Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
27
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Sandor Victor | Director | 10 | $0 | $0 | 2026-06-09 |
| Dorton Katina | Director | 2 | $0 | $0 | 2026-06-09 |
| Bonita David P | Director, 10% Owner | 23 | $43.50M | $0 | 2026-06-09 |
| Babler Martin | Director | 6 | $0 | $0 | 2026-06-09 |
| FRIEDMAN PAUL A | Director | 11 | $0 | $0 | 2026-06-09 |
| BAKER JULIAN | Director, 10% Owner | 9 | $10.00M | $0 | 2026-06-09 |
| Morris Charles Q | Chief Medical Officer | 1 | $0 | $0 | 2026-05-01 |
| Shah Rajeev M. | 10% Owner | 2 | $0 | $0 | 2026-04-27 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 2 | $12.50M | $0 | 2026-04-21 |
| 667, L.P. | Director, 10% Owner | 2 | $10.00M | $0 | 2026-04-21 |
| Combs Andrew | EVP, Head of Chemistry | 14 | $268.6K | $0 | 2026-02-04 |
| Vaddi Krishna | President, CEO | 28 | $871.9K | $0 | 2026-02-04 |
| Scherle Peggy | Chief Scientific Officer | 39 | $0 | $2.26M | 2026-02-04 |
| Lim Bryant David | Chief Legal Officer, Corp Sec. | 7 | $35.7K | $0 | 2026-02-04 |
| Huang Jane | President, CMO | 37 | $0 | $81.3K | 2025-10-04 |
| Dier Mardi | Director | 7 | $190.0K | $0 | 2025-06-12 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | 4 | $0 | $0 | 2025-06-12 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | 36 | $59.47M | $0 | 2024-06-14 |
| Chardonnet Laurent | Chief Financial Officer | 10 | $117.4K | $0 | 2024-03-01 |
| ORBIMED CAPITAL LLC | Director, 10% Owner | 1 | $5.00M | $0 | 2023-05-22 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 22 | $8.4K | $1.00M | 2022-02-15 |
| Mauro David J | Chief Medical Officer | 51 | $0 | $5.61M | 2021-10-05 |
| Pierce Christopher | EVP and Chief of Business Oper | 16 | $71.3K | $882.5K | 2021-09-02 |
| Piper Brian | Chief Financial Officer | 12 | $0 | $563.4K | 2021-08-25 |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | 4 | $0 | $0 | 2021-01-27 |
| OrbiMed Capital GP VI LLC | 10% Owner | 1 | $2.50M | $0 | 2021-01-11 |
| ORBIMED ADVISORS LLC | Director, 10% Owner | 12 | $23.50M | $0 | 2020-09-29 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| FRIEDMAN PAUL A | Director | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2026-06-09 | 2026-06-10 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Morris Charles Q | Chief Medical Officer | A Award deriv | 2026-05-01 | 2026-05-04 | 450,000 | $4.70 | $2.12M | 450,000 | SEC↗ |
| Shah Rajeev M. | 10% Owner | J Other deriv | 2026-04-27 | 2026-04-28 | 1,407,000 | — | $0 | 1,407,000 | SEC↗ |
| Shah Rajeev M. | 10% Owner | J Other | 2026-04-27 | 2026-04-28 | 1,407,000 | — | $0 | 6,475,882 | SEC↗ |
| 667, L.P. | Director, 10% Owner | P Buy deriv | 2026-04-21 | 2026-04-22 | 114,601 | $4.44 | $508.8K | 1,678,273 | SEC↗ |
| 667, L.P. | Director, 10% Owner | P Buy deriv | 2026-04-21 | 2026-04-22 | 2,137,651 | $4.44 | $9.49M | 20,105,994 | SEC↗ |
| OrbiMed Genesis GP LLC | Director, 10% Owner | P Buy | 2026-04-21 | 2026-04-23 | 1,126,126 | $4.44 | $5.00M | 1,126,126 | SEC↗ |
| OrbiMed Genesis GP LLC | Director, 10% Owner | P Buy | 2026-04-21 | 2026-04-23 | 1,689,189 | $4.44 | $7.50M | 11,808,945 | SEC↗ |
| Bonita David P | Director, 10% Owner | P Buy | 2026-04-21 | 2026-04-23 | 1,126,126 | $4.44 | $5.00M | 1,126,126 | SEC↗ |
| Bonita David P | Director, 10% Owner | P Buy | 2026-04-21 | 2026-04-23 | 1,689,189 | $4.44 | $7.50M | 11,808,945 | SEC↗ |
| Vaddi Krishna | CEO | A Award deriv | 2026-02-04 | 2026-02-05 | 837,000 | — | $0 | 837,000 | SEC↗ |
| Lim Bryant David | CLO, CFO, Corp Sec. | A Award deriv | 2026-02-04 | 2026-02-05 | 275,000 | — | $0 | 275,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2026-02-04 | 2026-02-05 | 230,000 | — | $0 | 230,000 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | A Award deriv | 2026-02-04 | 2026-02-05 | 230,000 | — | $0 | 230,000 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2025-11-05 | 2025-11-07 | 121,285 | — | $0 | 121,285 | SEC↗ |
| Dorton Katina | Director | A Award deriv | 2025-10-17 | 2025-10-20 | 76,000 | — | $0 | 76,000 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2025-10-04 | 2025-10-07 | 9,375 | — | $0 | 18,750 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2025-10-04 | 2025-10-07 | 3,355 | $1.47 | $4.9K | 86,917 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2025-10-04 | 2025-10-07 | 9,375 | — | $0 | 90,272 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2025-07-04 | 2025-07-08 | 9,375 | — | $0 | 28,125 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2025-07-04 | 2025-07-08 | 3,355 | $0.79 | $2.7K | 80,897 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2025-07-04 | 2025-07-08 | 9,375 | — | $0 | 84,252 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2025-06-12 | 2025-06-13 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2025-06-12 | 2025-06-13 | 38,000 | — | $0 | 38,000 | SEC↗ |
| FRIEDMAN PAUL A | Director | A Award deriv | 2025-06-12 | 2025-06-13 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Dier Mardi | Director | A Award deriv | 2025-06-12 | 2025-06-13 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2025-06-12 | 2025-06-13 | 38,000 | — | $0 | 38,000 | SEC↗ |
| Baker Brothers Life Sciences L | Director, 10% Owner | A Award deriv | 2025-06-12 | 2025-06-13 | 76,000 | — | $0 | 76,000 | SEC↗ |
| Baker Brothers Life Sciences L | Director, 10% Owner | A Award deriv | 2025-06-12 | 2025-06-13 | 76,000 | — | $0 | 76,000 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2025-04-04 | 2025-04-07 | 9,375 | — | $0 | 37,500 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2025-04-04 | 2025-04-07 | 9,375 | — | $0 | 78,232 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2025-04-04 | 2025-04-07 | 3,355 | $0.68 | $2.3K | 74,877 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-25 | 2025-03-27 | 675,000 | $0.69 | $465.7K | 1,999,296 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | P Buy | 2025-03-25 | 2025-03-27 | 100,000 | $0.69 | $69.0K | 480,123 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-21 | 2025-03-24 | 15,000 | $0.73 | $10.9K | 1,324,296 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-20 | 2025-03-24 | 5,416 | $0.73 | $4.0K | 1,309,296 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-17 | 2025-03-18 | 9,106 | $0.75 | $6.8K | 1,303,880 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-14 | 2025-03-18 | 29,999 | $0.75 | $22.5K | 1,294,774 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-13 | 2025-03-14 | 50,000 | $0.72 | $36.0K | 1,264,775 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2025-03-12 | 2025-03-14 | 47,500 | $0.71 | $33.7K | 1,214,775 | SEC↗ |
| Vaddi Krishna | CEO | A Award deriv | 2025-02-04 | 2025-02-05 | 496,000 | — | $0 | 496,000 | SEC↗ |
| Huang Jane | President, CMO | A Award deriv | 2025-02-04 | 2025-02-05 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | A Award deriv | 2025-02-04 | 2025-02-05 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2025-02-04 | 2025-02-05 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Lim Bryant David | CLO, CFO, Corp Sec. | A Award deriv | 2025-02-04 | 2025-02-05 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2025-01-04 | 2025-01-07 | 9,375 | — | $0 | 46,875 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2025-01-04 | 2025-01-07 | 3,859 | $1.39 | $5.4K | 68,857 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2025-01-04 | 2025-01-07 | 9,375 | — | $0 | 72,716 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2024-12-31 | 2025-01-03 | 5,000 | $1.21 | $6.0K | 142,553 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2024-12-30 | 2025-01-02 | 10,000 | $1.20 | $12.0K | 137,553 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | P Buy | 2024-12-23 | 2024-12-26 | 60,000 | $1.37 | $82.2K | 377,623 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | P Buy | 2024-12-20 | 2024-12-26 | 3,075 | $1.15 | $3.5K | 317,623 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2024-12-19 | 2024-12-20 | 6,888 | $0.89 | $6.1K | 127,553 | SEC↗ |
| Lim Bryant David | CLO, Interim CFO, Corp Sec. | P Buy | 2024-12-19 | 2024-12-20 | 25,000 | $0.91 | $22.8K | 27,400 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2024-12-18 | 2024-12-20 | 100,000 | $0.93 | $93.0K | 1,167,275 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2024-10-04 | 2024-10-07 | 9,375 | — | $0 | 56,250 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2024-10-04 | 2024-10-07 | 9,375 | — | $0 | 66,690 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2024-10-04 | 2024-10-07 | 3,349 | $2.00 | $6.7K | 63,341 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2024-07-04 | 2024-07-08 | 9,375 | — | $0 | 65,625 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2024-07-04 | 2024-07-08 | 3,347 | $3.60 | $12.0K | 57,315 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2024-07-04 | 2024-07-08 | 9,375 | — | $0 | 60,662 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Dier Mardi | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| FRIEDMAN PAUL A | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | A Award deriv | 2024-06-14 | 2024-06-18 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Lim Bryant David | CLO, Interim CFO, Corp Sec. | A Award deriv | 2024-05-14 | 2024-05-16 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2024-04-04 | 2024-04-08 | 9,375 | — | $0 | 75,000 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2024-04-04 | 2024-04-08 | 3,347 | $4.74 | $15.9K | 51,287 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2024-04-04 | 2024-04-08 | 9,375 | — | $0 | 54,634 | SEC↗ |
| Vaddi Krishna | CEO | A Award deriv | 2024-03-01 | 2024-03-04 | 425,000 | — | $0 | 425,000 | SEC↗ |
| Huang Jane | President, CMO | A Award deriv | 2024-03-01 | 2024-03-04 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award deriv | 2024-03-01 | 2024-03-04 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Combs Andrew | Chief Chemistry Officer | A Award deriv | 2024-03-01 | 2024-03-04 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2024-03-01 | 2024-03-04 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Lim Bryant David | Chief Legal Officer, Corp Se | A Award deriv | 2024-03-01 | 2024-03-04 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2024-01-04 | 2024-01-08 | 9,375 | — | $0 | 84,375 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2024-01-04 | 2024-01-08 | 3,844 | $3.77 | $14.5K | 45,259 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2024-01-04 | 2024-01-08 | 9,375 | — | $0 | 49,103 | SEC↗ |
| Baker Brothers Life Sciences L | Director, 10% Owner | A Award deriv | 2023-12-13 | 2023-12-13 | 7,343,307 | $3.15 | $23.13M | 17,968,343 | SEC↗ |
| Baker Brothers Life Sciences L | Director, 10% Owner | A Award deriv | 2023-12-13 | 2023-12-13 | 593,452 | $3.15 | $1.87M | 1,563,672 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2023-10-04 | 2023-10-06 | 9,375 | — | $0 | 93,750 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2023-10-04 | 2023-10-06 | 9,375 | — | $0 | 39,728 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2023-07-04 | 2023-07-06 | 9,375 | — | $0 | 103,125 | SEC↗ |
| Huang Jane | President, CMO | F Tax w/h | 2023-07-04 | 2023-07-06 | 3,242 | $4.65 | $15.1K | 30,353 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2023-07-04 | 2023-07-06 | 9,375 | — | $0 | 33,595 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Dier Mardi | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| FRIEDMAN PAUL A | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | A Award deriv | 2023-06-16 | 2023-06-21 | 23,500 | — | $0 | 23,500 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2023-05-25 | 2023-05-26 | 900 | $5.31 | $4.8K | 1,067,275 | SEC↗ |
| Lim Bryant David | Chief Legal Officer, Corp Se | P Buy | 2023-05-24 | 2023-05-25 | 2,400 | $5.39 | $12.9K | 2,400 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2023-05-24 | 2023-05-26 | 1,000 | $5.01 | $5.0K | 1,066,375 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2023-05-23 | 2023-05-25 | 11,856 | $5.63 | $66.7K | 1,065,375 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | P Buy | 2023-05-23 | 2023-05-25 | 5,000 | $5.50 | $27.5K | 42,165 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2023-05-22 | 2023-05-24 | 121,178 | $5.75 | $696.8K | 630,658 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2023-05-22 | 2023-05-24 | 970,220 | $5.75 | $5.58M | 970,220 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2023-05-22 | 2023-05-24 | 10,625,036 | $5.75 | $61.09M | 10,625,036 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2023-05-22 | 2023-05-24 | 1,327,044 | $5.75 | $7.63M | 6,539,415 | SEC↗ |
| Bonita David P | Director, 10% Owner | P Buy | 2023-05-22 | 2023-05-24 | 869,565 | $5.75 | $5.00M | 10,119,756 | SEC↗ |
| ORBIMED CAPITAL LLC | Director, 10% Owner | P Buy | 2023-05-22 | 2023-05-24 | 869,565 | $5.75 | $5.00M | 10,119,756 | SEC↗ |
| Huang Jane | President, CMO | S Sale | 2023-04-06 | 2023-04-06 | 13,280 | $6.12 | $81.3K | 24,220 | SEC↗ |
| Huang Jane | President, CMO | M Exercise deriv | 2023-04-04 | 2023-04-06 | 37,500 | — | $0 | 112,500 | SEC↗ |
| Huang Jane | President, CMO | M Exercise | 2023-04-04 | 2023-04-06 | 37,500 | — | $0 | 37,500 | SEC↗ |
| Lim Bryant David | Chief Legal Officer, Corp Se | A Award deriv | 2023-03-01 | 2023-03-02 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Vaddi Krishna | CEO | A Award deriv | 2023-02-07 | 2023-02-09 | 330,000 | — | $0 | 330,000 | SEC↗ |
| Huang Jane | President, CMO | A Award deriv | 2023-02-07 | 2023-02-09 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award deriv | 2023-02-07 | 2023-02-09 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | A Award deriv | 2023-02-07 | 2023-02-09 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2023-02-07 | 2023-02-09 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award deriv | 2022-12-21 | 2022-12-22 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Vaddi Krishna | CEO | P Buy | 2022-12-20 | 2022-12-21 | 19,188 | $5.13 | $98.4K | 120,665 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | P Buy | 2022-12-08 | 2022-12-12 | 10,000 | $4.76 | $47.6K | 35,873 | SEC↗ |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | A Award deriv | 2022-06-17 | 2022-06-22 | 34,300 | — | $0 | 34,300 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2022-06-17 | 2022-06-22 | 34,300 | — | $0 | 34,300 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2022-06-17 | 2022-06-22 | 31,293 | — | $0 | 31,293 | SEC↗ |
| Dier Mardi | Director | A Award deriv | 2022-06-17 | 2022-06-22 | 34,300 | — | $0 | 34,300 | SEC↗ |
| FRIEDMAN PAUL A | Director | A Award deriv | 2022-06-17 | 2022-06-22 | 34,300 | — | $0 | 34,300 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2022-06-17 | 2022-06-22 | 34,300 | — | $0 | 34,300 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | P Buy | 2022-06-01 | 2022-06-01 | 10,000 | $4.23 | $42.3K | 24,500 | SEC↗ |
| Huang Jane | President, CMO | A Award deriv | 2022-05-02 | 2022-05-04 | 460,000 | — | $0 | 460,000 | SEC↗ |
| Huang Jane | President, CMO | A Award deriv | 2022-05-02 | 2022-05-04 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | M Exercise deriv | 2022-04-01 | 2022-04-04 | 36,062 | — | $0 | 50,397 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | M Exercise | 2022-03-31 | 2022-04-04 | 36,062 | $1.89 | $68.2K | 304,442 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award | 2022-03-21 | 2022-03-22 | 6,500 | $7.51 | $48.8K | 14,500 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | A Award deriv | 2022-02-15 | 2022-02-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | A Award deriv | 2022-02-15 | 2022-02-17 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Vaddi Krishna | CEO | A Award deriv | 2022-02-15 | 2022-02-17 | 327,900 | — | $0 | 327,900 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award deriv | 2022-02-15 | 2022-02-17 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2022-02-15 | 2022-02-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2022-01-03 | 2022-01-05 | 11,206 | — | $0 | 11,206 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-12-15 | 2021-12-17 | 24,853 | — | $0 | 74,575 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-12-15 | 2021-12-17 | 882 | — | $0 | 195,163 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-12-15 | 2021-12-17 | 3,016 | — | $0 | 1,307 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-12-15 | 2021-12-17 | 3,016 | $1.89 | $5.7K | 3,460 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-12-15 | 2021-12-17 | 28,751 | $13.00 | $373.8K | 444 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-12-15 | 2021-12-17 | 25,735 | $12.85 | $330.7K | 29,195 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | P Buy | 2021-12-14 | 2021-12-15 | 4,000 | $11.60 | $46.4K | 268,380 | SEC↗ |
| Vaddi Krishna | President, CEO | A Award | 2021-12-13 | 2021-12-14 | 8,000 | $12.13 | $97.0K | 1,053,519 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award | 2021-12-13 | 2021-12-14 | 5,000 | $12.28 | $61.4K | 8,000 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | P Buy | 2021-12-13 | 2021-12-15 | 4,000 | $12.12 | $48.5K | 264,380 | SEC↗ |
| Chardonnet Laurent | Chief Financial Officer | A Award deriv | 2021-11-29 | 2021-12-01 | 180,000 | — | $0 | 180,000 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-11-16 | 2021-11-18 | 28,751 | — | $0 | 196,045 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-11-16 | 2021-11-18 | 28,351 | $15.87 | $449.9K | 844 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-11-16 | 2021-11-18 | 28,751 | $12.85 | $369.5K | 29,195 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-11-16 | 2021-11-18 | 400 | $16.43 | $6.6K | 444 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2021-10-13 | 2021-10-14 | 8,022 | — | $0 | 8,022 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-10-05 | 2021-10-06 | 15,000 | — | $0 | 137,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-10-05 | 2021-10-06 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-10-05 | 2021-10-06 | 5,908 | $30.26 | $178.8K | 9,092 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-10-05 | 2021-10-06 | 7,803 | $31.30 | $244.2K | 1,289 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-10-05 | 2021-10-06 | 1,289 | $32.06 | $41.3K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-09-07 | 2021-09-09 | 15,000 | — | $0 | 167,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-09-07 | 2021-09-09 | 4,640 | $37.79 | $175.3K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-09-07 | 2021-09-09 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-09-07 | 2021-09-09 | 7,487 | $35.91 | $268.9K | 7,513 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-09-07 | 2021-09-09 | 2,873 | $36.92 | $106.1K | 4,640 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise deriv | 2021-09-02 | 2021-09-07 | 17,000 | — | $0 | 207,796 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-09-02 | 2021-09-07 | 6,930 | $42.50 | $294.5K | 3,750 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise | 2021-09-02 | 2021-09-07 | 17,000 | $12.85 | $218.4K | 20,750 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-09-02 | 2021-09-07 | 3,343 | $40.29 | $134.7K | 17,407 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-09-02 | 2021-09-07 | 6,727 | $41.52 | $279.3K | 10,680 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-08-27 | 2021-08-30 | 6,014 | — | $0 | 27,018 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-08-27 | 2021-08-30 | 2,707 | $36.23 | $98.1K | 173,527 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-08-27 | 2021-08-30 | 2,700 | $35.32 | $95.4K | 176,234 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-08-27 | 2021-08-30 | 6,014 | $1.43 | $8.6K | 178,934 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-08-27 | 2021-08-30 | 607 | $37.08 | $22.5K | 172,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-08-26 | 2021-08-30 | 1,700 | — | $0 | 33,032 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-08-26 | 2021-08-30 | 1,700 | $1.43 | $2.4K | 174,620 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-08-26 | 2021-08-30 | 1,700 | $35.19 | $59.8K | 172,920 | SEC↗ |
| Piper Brian | Chief Financial Officer | M Exercise deriv | 2021-08-25 | 2021-08-27 | 8,333 | — | $0 | 264,329 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-08-25 | 2021-08-27 | 3,889 | $33.23 | $129.2K | 2,344 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-08-25 | 2021-08-27 | 2,100 | $32.44 | $68.1K | 6,233 | SEC↗ |
| Piper Brian | Chief Financial Officer | M Exercise | 2021-08-25 | 2021-08-27 | 8,333 | $1.89 | $15.7K | 8,333 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-08-25 | 2021-08-27 | 2,344 | $34.33 | $80.5K | 0 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-08-13 | 2021-08-17 | 1,728 | — | $0 | 34,732 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-08-13 | 2021-08-17 | 558 | — | $0 | 42,672 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-08-13 | 2021-08-17 | 2,286 | $35.07 | $80.2K | 172,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-08-13 | 2021-08-17 | 558 | $1.89 | $1.1K | 173,478 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-08-13 | 2021-08-17 | 1,728 | $1.43 | $2.5K | 175,206 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-08-05 | 2021-08-09 | 15,000 | — | $0 | 167,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-08-05 | 2021-08-09 | 2,063 | $31.03 | $64.0K | 6,821 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-08-05 | 2021-08-09 | 6,721 | $32.15 | $216.1K | 100 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-08-05 | 2021-08-09 | 100 | $32.63 | $3.3K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-08-05 | 2021-08-09 | 6,116 | $29.93 | $183.1K | 8,884 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-08-05 | 2021-08-09 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-07-27 | 2021-07-29 | 20,000 | — | $0 | 36,460 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-07-27 | 2021-07-29 | 20,000 | $1.43 | $28.6K | 192,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-07-27 | 2021-07-29 | 680 | $36.09 | $24.5K | 172,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-07-27 | 2021-07-29 | 19,320 | $35.45 | $684.9K | 173,600 | SEC↗ |
| Combs Andrew | EVP, Head of Chemistry | A Award deriv | 2021-07-20 | 2021-07-22 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Piper Brian | Chief Financial Officer | A Award deriv | 2021-07-20 | 2021-07-22 | 115,650 | — | $0 | 115,650 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | A Award deriv | 2021-07-20 | 2021-07-22 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | A Award deriv | 2021-07-20 | 2021-07-22 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | A Award deriv | 2021-07-20 | 2021-07-22 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Vaddi Krishna | President, CEO | A Award deriv | 2021-07-20 | 2021-07-22 | 285,800 | — | $0 | 285,800 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award deriv | 2021-07-20 | 2021-07-22 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Babler Martin | Director | A Award deriv | 2021-07-19 | 2021-07-20 | 36,400 | — | $0 | 36,400 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-07-06 | 2021-07-08 | 15,000 | — | $0 | 182,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-08 | 10,445 | $27.17 | $283.8K | 4,555 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-07-06 | 2021-07-08 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-08 | 4,255 | $28.13 | $119.7K | 300 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-07-06 | 2021-07-08 | 300 | $28.84 | $8.7K | 0 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | A Award deriv | 2021-06-18 | 2021-06-22 | 23,344 | — | $0 | 23,344 | SEC↗ |
| Bonita David P | Director, 10% Owner | A Award deriv | 2021-06-18 | 2021-06-22 | 23,344 | — | $0 | 23,344 | SEC↗ |
| Dier Mardi | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 23,344 | — | $0 | 23,344 | SEC↗ |
| FRIEDMAN PAUL A | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 23,344 | — | $0 | 23,344 | SEC↗ |
| Sandor Victor | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 23,344 | — | $0 | 23,344 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-06-07 | 2021-06-09 | 15,000 | — | $0 | 197,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-06-07 | 2021-06-09 | 12,700 | $32.73 | $415.7K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-06-07 | 2021-06-09 | 1,400 | $30.35 | $42.5K | 13,600 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-06-07 | 2021-06-09 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-06-07 | 2021-06-09 | 900 | $31.62 | $28.5K | 12,700 | SEC↗ |
| Piper Brian | Chief Financial Officer | M Exercise deriv | 2021-05-25 | 2021-05-27 | 8,333 | — | $0 | 272,662 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-05-25 | 2021-05-27 | 1,736 | $35.45 | $61.5K | 399 | SEC↗ |
| Piper Brian | Chief Financial Officer | M Exercise | 2021-05-25 | 2021-05-27 | 8,333 | $1.89 | $15.7K | 8,333 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-05-25 | 2021-05-27 | 3,088 | $34.11 | $105.3K | 2,135 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-05-25 | 2021-05-27 | 399 | $36.09 | $14.4K | 0 | SEC↗ |
| Piper Brian | Chief Financial Officer | S Sale | 2021-05-25 | 2021-05-27 | 3,110 | $33.53 | $104.3K | 5,223 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-05-07 | 2021-05-11 | 10,000 | — | $0 | 56,460 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-05-07 | 2021-05-11 | 3,964 | $40.30 | $159.7K | 178,956 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-05-07 | 2021-05-11 | 5,836 | $41.14 | $240.1K | 173,120 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-05-07 | 2021-05-11 | 200 | $41.85 | $8.4K | 172,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise | 2021-05-07 | 2021-05-11 | 10,000 | $1.43 | $14.3K | 182,920 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-05-05 | 2021-05-10 | 15,000 | — | $0 | 212,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-05-05 | 2021-05-10 | 3,415 | $39.36 | $134.4K | 11,585 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-05-05 | 2021-05-10 | 15,000 | $1.89 | $28.4K | 15,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-05-05 | 2021-05-10 | 1,109 | $41.07 | $45.5K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-05-05 | 2021-05-10 | 10,476 | $40.30 | $422.2K | 1,109 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-04-29 | 2021-04-30 | 3,223 | — | $0 | 4,323 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise deriv | 2021-04-29 | 2021-04-30 | 3,295 | — | $0 | 4,323 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-04-29 | 2021-04-30 | 3,223 | $1.89 | $6.1K | 3,667 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-04-29 | 2021-04-30 | 3,223 | $40.29 | $129.9K | 444 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-04-29 | 2021-04-30 | 3,295 | $40.29 | $132.8K | 3,750 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise | 2021-04-29 | 2021-04-30 | 3,295 | $1.89 | $6.2K | 7,045 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-04-27 | 2021-04-29 | 25,000 | — | $0 | 227,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-27 | 2021-04-29 | 1,711 | $36.11 | $61.8K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-04-27 | 2021-04-29 | 25,000 | $1.89 | $47.3K | 25,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-27 | 2021-04-29 | 7,688 | $34.66 | $266.5K | 17,312 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-27 | 2021-04-29 | 15,601 | $35.68 | $556.6K | 1,711 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-04-19 | 2021-04-21 | 25,000 | — | $0 | 252,610 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-19 | 2021-04-21 | 4,000 | $31.27 | $125.1K | 0 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-04-19 | 2021-04-21 | 25,000 | $1.89 | $47.3K | 25,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-19 | 2021-04-21 | 21,000 | $30.82 | $647.2K | 4,000 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-04-08 | 2021-04-15 | 9,617 | — | $0 | 277,610 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-04-08 | 2021-04-15 | 100 | — | $0 | 7,546 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise deriv | 2021-04-08 | 2021-04-15 | 200 | — | $0 | 7,618 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-04-08 | 2021-04-15 | 4,630 | — | $0 | 66,460 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-08 | 2021-04-15 | 3,274 | $37.04 | $121.3K | 6,343 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-04-08 | 2021-04-15 | 9,617 | $1.89 | $18.2K | 9,617 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-08 | 2021-04-15 | 1,501 | $37.83 | $56.8K | 4,842 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-08 | 2021-04-15 | 1,293 | $39.00 | $50.4K | 3,549 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-08 | 2021-04-15 | 3,549 | $39.56 | $140.4K | 0 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-04-08 | 2021-04-15 | 100 | $40.00 | $4.0K | 444 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-04-08 | 2021-04-15 | 100 | $1.89 | $189 | 544 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-04-08 | 2021-04-15 | 200 | $40.00 | $8.0K | 3,750 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | A Award | 2021-04-08 | 2021-04-15 | 200 | $1.89 | $378 | 3,950 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-08 | 2021-04-15 | 669 | $38.97 | $26.1K | 174,589 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-08 | 2021-04-15 | 875 | $37.72 | $33.0K | 175,258 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-08 | 2021-04-15 | 1,417 | $36.97 | $52.4K | 176,133 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-08 | 2021-04-15 | 1,669 | $39.57 | $66.0K | 172,920 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award | 2021-04-08 | 2021-04-15 | 4,630 | $1.43 | $6.6K | 177,550 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise deriv | 2021-04-07 | 2021-04-09 | 15,383 | — | $0 | 287,227 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise deriv | 2021-04-07 | 2021-04-09 | 1,000 | — | $0 | 7,646 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | M Exercise deriv | 2021-04-07 | 2021-04-09 | 828 | — | $0 | 7,818 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | M Exercise deriv | 2021-04-07 | 2021-04-09 | 15,370 | — | $0 | 71,090 | SEC↗ |
| Mauro David J | Chief Medical Officer | M Exercise | 2021-04-07 | 2021-04-09 | 15,383 | $1.89 | $29.1K | 15,383 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-07 | 2021-04-09 | 8,300 | $39.03 | $323.9K | 7,083 | SEC↗ |
| Mauro David J | Chief Medical Officer | S Sale | 2021-04-07 | 2021-04-09 | 7,083 | $39.69 | $281.1K | 0 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | M Exercise | 2021-04-07 | 2021-04-09 | 1,000 | $1.89 | $1.9K | 1,444 | SEC↗ |
| Morosini Deborah | EVP, Chief of Clinical Affai | S Sale | 2021-04-07 | 2021-04-09 | 1,000 | $40.04 | $40.0K | 444 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | S Sale | 2021-04-07 | 2021-04-09 | 828 | $40.08 | $33.2K | 3,750 | SEC↗ |
| Pierce Christopher | EVP and Chief of Business Op | A Award | 2021-04-07 | 2021-04-09 | 828 | $1.89 | $1.6K | 4,578 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | A Award | 2021-04-07 | 2021-04-09 | 15,370 | $1.43 | $22.0K | 188,290 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-07 | 2021-04-09 | 6,881 | $39.63 | $272.7K | 173,120 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-07 | 2021-04-09 | 8,289 | $39.02 | $323.4K | 180,001 | SEC↗ |
| Scherle Peggy | Chief Scientific Officer | S Sale | 2021-04-07 | 2021-04-09 | 200 | $40.30 | $8.1K | 172,920 | SEC↗ |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | M Exercise deriv | 2021-01-27 | 2021-01-29 | 5,188 | — | $0 | 41,500 | SEC↗ |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | M Exercise deriv | 2021-01-27 | 2021-01-29 | 5,188 | — | $0 | 41,500 | SEC↗ |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | M Exercise | 2021-01-27 | 2021-01-29 | 5,188 | $12.85 | $66.7K | 876,061 | SEC↗ |
| BAKER BROS. ADVISORS LP | Director, 10% Owner | M Exercise | 2021-01-27 | 2021-01-29 | 5,188 | $12.85 | $66.7K | 9,252,951 | SEC↗ |
| Director, 10% Owner | P Buy deriv | 2021-01-11 | 2021-01-12 | 41,700 | $60.00 | $2.50M | 5,596,886 | SEC↗ | |
| OrbiMed Capital GP VI LLC | 10% Owner | P Buy deriv | 2021-01-11 | 2021-01-12 | 41,700 | $60.00 | $2.50M | 5,596,886 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | P Buy deriv | 2021-01-11 | 2021-01-13 | 154,222 | $60.00 | $9.25M | 5,212,371 | SEC↗ |
| BAKER JULIAN | Director, 10% Owner | P Buy deriv | 2021-01-11 | 2021-01-13 | 12,444 | $60.00 | $746.6K | 509,480 | SEC↗ |
| Vaddi Krishna | President, CEO | C Conversion deriv | 2020-09-29 | 2020-09-29 | 32,876 | — | $0 | 0 | SEC↗ |
| Vaddi Krishna | President, CEO | C Conversion deriv | 2020-09-29 | 2020-09-29 | 32,876 | — | $0 | 0 | SEC↗ |
| Vaddi Krishna | President, CEO | C Conversion deriv | 2020-09-29 | 2020-09-29 | 101,477 | — | $0 | 0 | SEC↗ |
| ORBIMED ADVISORS LLC | Director, 10% Owner | C Conversion deriv | 2020-09-29 | 2020-09-29 | 5,555,186 | — | $0 | 5,555,186 | SEC↗ |